Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GILD vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GILD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

GILD Overall Winner 6-Pillar Tally: GILD 5 – 1 MRNA Matrix Metrics: GILD 9 – 1 MRNA

As of Nov 20, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GILD carries a Unified Composite Score of 42.9/100 (HOLD) at $166.43 (16.4x Forward P/E, 38.2% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

  • Growth vs. Quality Trade-Off: GILD earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. MRNA 40.3/100 SELL) and 0.31β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GILD vs MRNA
GILD NASDAQ Head-to-Head Winner
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$166.43
-0.06% 1D
Market Cap $206.6B
TTM Revenue $31.0B
Forward P/E 16.4x
Beta / 30D Vol 0.31β · 30% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 32.0 Fund 49.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.7% over 20 days), RSI 54
RSI-14: 54.5 · SMA20: $167.29 · SMA50: $157.26
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (GILD 5 – 1 MRNA)

Columns: Metric · GILD · MRNA
1. Valuation Multiples GILD
Forward P/E 16.4x 23.0x
Trailing P/E 16.8x 23.0x
PEG Ratio 2.27x N/M
EV / Revenue 7.3x 33.1x
2. Growth & Scale GILD
Revenue Growth (YoY) +6.8% +29.2%
Earnings Growth (YoY) -20.2% -85.1%
TTM Revenue (USD) $31.0B $2.52B
Market Cap $206.6B $80.7B
3. Profitability & Quality GILD
Gross Margin 79.9% -42.0%
Operating Margin 38.2% -80.8%
Net Profit Margin -12.5% -110.5%
Return on Equity (ROE) -22.4% -34.5%
4. Balance Sheet & Cash Flow GILD
Cash Generation (TTM) $13.8B -$2.04B
Cash Flow Margin 44.5% -81.0%
Net Cash / Leverage $19.8B Net Debt (2.01x D/E) $3.03B Net Debt (0.62x D/E)
Dividend Yield 1.92% None (0.00%)
5. Options & Positioning GILD
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 170.9% (61st %ile) 89.6% (52nd %ile)
Put/Call OI Skew 0.52x (Call-Skewed) 1.05x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 41.7% of Rev ($12.9B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - General Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GILD (9) vs MRNA (1)
Institutional Metric GILD MRNA Criterion Row Edge
Market Capitalization
Scale
$206.6B $80.7B Larger Scale GILD
Trailing P/E Ratio
Valuation
16.8x 23.0x Lower Multiple GILD
Forward P/E Ratio
Valuation
16.4x 23.0x Lower Multiple GILD
Revenue Growth (YoY)
Growth
+6.8% +29.2% Higher Growth MRNA
Operating Margin (TTM)
Profitability
38.2% -80.8% Higher Margin GILD
Net Profit Margin
Profitability
-12.5% -110.5% Higher Margin GILD
Return on Equity (ROE)
Capital Efficiency
-22.4% -34.5% Higher ROE GILD
52-Week Range Position
Momentum
83% ($117–$177) 67% ($22–$281) Stronger Trend GILD
Beta / 30D Volatility
Risk Regime
0.31β · 30% Vol 2.23β · 78% Vol Lower Realized Risk GILD
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite GILD
Trailing 12M Revenue (USD)
Operating Scale
$31.0B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
79.9% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.27x PEG · 7.3x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$13.8B ($19.8B Net Debt (2.01x D/E)) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GILD +9.65 pp
GILD: +5.88% · MRNA: -3.77%
3M Horizon MRNA +26.98 pp
GILD: +13.42% · MRNA: +40.4%
6M Horizon MRNA +292.09 pp
GILD: +23.87% · MRNA: +315.96%
1Y Horizon MRNA +676.5 pp
GILD: +29.95% · MRNA: +706.45%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GILD Revenue MRNA Revenue GILD Op. Margin MRNA Op. Margin Margin Leader
FY2018 $22.1B $140M 37.1% -306.0% GILD
FY2019 $22.4B $60M 19.1% -906.8% GILD
FY2020 $24.7B $800M 16.5% -95.0% GILD
FY2021 $27.3B $18.5B 36.3% 72.0% MRNA
FY2022 $27.3B $19.3B 26.9% 48.9% MRNA
FY2023 $27.1B $6.85B 28.0% -61.9% GILD
FY2024 $28.8B $3.24B 5.8% -121.9% GILD
FY2025 $29.4B $1.94B 34.0% -158.1% GILD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GILD SURGE
12d in phase · OBV DISTRIBUTION
Current IV 170.9%
IV Percentile 61st %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GILD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $167.58 · IV 33.3%

GILD vs. MRNA: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of GILD ($16,758) vs. MRNA ($21,527) against risk-defined 5-day vertical and put-wall option structures.

GILD Spot $167.58 · IV 33.3%
GILD Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $170 / $180 Bull Call Spread

Buy 1x $170C · Sell 1x $180C · 31d

Net Entry $334 Debit
T+5d @ +5% Move +$214 (+64%)
Max Risk / Buffer $334 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $155 / $145 Bull Put Spread

Sell 1x $155P · Buy 1x $145P · 31d

Net Entry $145 Credit
Max Credit / Yield +$145 (+17.0% RoM)
Max Risk / Buffer -8.4% Cushion ($855 Mgn)
5d Edge & Liquidity 80% PoP · Liq A
Simulate 5-Day Payoff →
MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GILD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $206.6B market capitalization and 38.2% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($12.9B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ GILD vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GILD carries a Unified Composite Score of 42.9/100 (HOLD) at $166.43 (16.4x Forward P/E, 38.2% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Growth vs. Quality Trade-Off: GILD earns the overall head-to-head edge with a stronger Unified Composite Score (42.9/100 HOLD vs. MRNA 40.3/100 SELL) and 0.31β · 30% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.

GILD leads the Growth & Scale pillar: GILD posts +6.8% YoY revenue growth and -20.2% YoY earnings growth on $31.0B TTM revenue (79.9% gross margin, 38.2% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GILD cumulative revenue shifted +33.0% while MRNA shifted +1285.7%. In operating R&D and SG&A reinvestment, GILD deploys 41.7% of Rev ($12.9B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

GILD screens cheaper on headline valuation multiples. GILD trades at 16.4x Forward P/E, 16.8x Trailing P/E, 2.27x PEG, and 7.3x EV/Revenue (44.5% FCF margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GILD (-22.4% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, GILD carries 170.9% implied volatility (61st %ile, Elevated (60th–80th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.31β · 30% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.